^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    22h
    TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Antalya Training and Research Hospital
    New trial • Real-world evidence • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab)
    22h
    GOBLET: A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (clinicaltrials.gov)
    P1/2, N=122, Recruiting, Oncolytics Biotech
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • Reolysin (pelareorep)
    1d
    The interaction of PD-1/PD-L1 and its inhibition by anti-PD-L1 antibody at the single-molecule level. (PubMed, FEBS Lett)
    In this work, the two complete complex structures in the protein native state of PD-1 with PD-L1, and the anti-PD-L1 antibody atezolizumab were investigated by atomic force microscopy (AFM) single-molecule force spectroscopy and predicted by AlphaFold modeling...Impact statement Our research developed a novel and close-to-native physiological platform to evaluate protein interactions from structural, mechanical, and kinetic perspectives at the single-molecule level. This could be applied in the design of more effective checkpoint inhibitory molecules and provides relevant methodologies for evaluating single-molecule macromolecular interactions.
    Journal
    |
    PD-1 (Programmed cell death 1)
    |
    Tecentriq (atezolizumab)
    2d
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    3d
    A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=62, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Sep 2028 --> Nov 2025
    Trial completion • Trial completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    3d
    COSMIC-312: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy (clinicaltrials.gov)
    P3, N=837, Active, not recruiting, Exelixis | Trial completion date: Dec 2024 --> Jul 2026
    Trial completion date
    |
    Tecentriq (atezolizumab) • sorafenib • Cabometyx (cabozantinib tablet)
    4d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2
    Enrollment open • Phase classification • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    4d
    Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab (clinicaltrials.gov)
    P2, N=15, Recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna
    New P2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    4d
    Molecularly guided precision therapy in metastatic adamantinoma: a case report. (PubMed, Per Med)
    She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.
    Journal • PARP Biomarker • PD(L)-1 Biomarker
    |
    XRCC2 (X-Ray Repair Cross Complementing 2)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab)
    5d
    The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study (clinicaltrials.gov)
    P=N/A, N=300, Completed, Sun Yat-sen University
    New trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    5d
    Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab)
    5d
    IMMUNO-TH: Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Dec 2028 --> Jan 2030 | Trial primary completion date: May 2028 --> Jan 2030
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)